Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting

Kirsten E. Lyke, Robert L. Atmar, Clara Dominguez Islas, Christine M. Posavad, Daniel Szydlo, Rahul PaulChourdhury, Meagan E. Deming, Amanda Eaton, Lisa A. Jackson, Angela R. Branche, Hana M. El Sahly, Christina A. Rostad, Judith M. Martin, Christine Johnston, Richard E. Rupp, Mark J. Mulligan, Rebecca C. Brady, Robert W. Frenck Jr., Martín Bäcker, Angelica C. Kottkamp, Tara M. Babu, Kumaravel Rajakumar, Srilatha Edupuganti, David Dobrzynski, Rhea N. Coler, Janet I. Archer, Sonja Crandon, Jillian A. Zemanek, Elizabeth R. Brown, Kathleen M. Neuzil, David S. Stephens, Diane J. Post, Seema U. Nayak, Paul C. Roberts, John H. Beigel, David Montefiori, the DMID 21-0012 Study Group
doi: https://doi.org/10.1101/2022.01.13.22268861
Kirsten E. Lyke
1Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ratmar@bcm.edu
Robert L. Atmar
2Departments of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ratmar@bcm.edu
Clara Dominguez Islas
3Vaccine and Infectious Disease Division, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine M. Posavad
3Vaccine and Infectious Disease Division, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
4Departments of Laboratory Medicine & Pathology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Szydlo
5Statistical Center for HIV/AIDS Research and Prevention (SCHARP), University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rahul PaulChourdhury
5Statistical Center for HIV/AIDS Research and Prevention (SCHARP), University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meagan E. Deming
1Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Eaton
6Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa A. Jackson
7Kaiser Permanente Washington Health Research Institute, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela R. Branche
8Department of Medicine, Division of Infectious Diseases, University of Rochester, Rochester, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hana M. El Sahly
2Departments of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina A. Rostad
9Department of Pediatrics and Center for Childhood Infections and Vaccines, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith M. Martin
10Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Johnston
3Vaccine and Infectious Disease Division, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
4Departments of Laboratory Medicine & Pathology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
11Department of Medicine, University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard E. Rupp
12Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J. Mulligan
13NYU Langone Vaccine Center and Division of Infectious Diseases and Immunology, Department of Medicine, NYU Grossman School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca C. Brady
14Cincinnati Children’s Hospital Medical Center, Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert W. Frenck Jr.
14Cincinnati Children’s Hospital Medical Center, Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martín Bäcker
15NYU Langone Hospital—Long Island Vaccine Center Research Clinic and Division of Infectious Disease, Department of Medicine, NYU Long Island School of Medicine, Mineola, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angelica C. Kottkamp
13NYU Langone Vaccine Center and Division of Infectious Diseases and Immunology, Department of Medicine, NYU Grossman School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tara M. Babu
11Department of Medicine, University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kumaravel Rajakumar
10Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Srilatha Edupuganti
16Department of Medicine, Emory University School of Medicine, Atlanta, GA
17Hope Clinic of Emory Vaccine Center, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Dobrzynski
8Department of Medicine, Division of Infectious Diseases, University of Rochester, Rochester, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rhea N. Coler
18Seattle Children’s Research Institute, University of Washington School of Medicine, Seattle WA
19Department of Pediatrics, University of Washington School of Medicine, Seattle WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janet I. Archer
20FHI360, Durham, NC 27701
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonja Crandon
21Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jillian A. Zemanek
5Statistical Center for HIV/AIDS Research and Prevention (SCHARP), University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth R. Brown
3Vaccine and Infectious Disease Division, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen M. Neuzil
1Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David S. Stephens
16Department of Medicine, Emory University School of Medicine, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diane J. Post
21Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seema U. Nayak
21Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul C. Roberts
21Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John H. Beigel
21Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Montefiori
6Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC
22Department of Surgery, Duke University Medical Center, Durham, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

As part of an ongoing study assessing homologous and heterologous booster vaccines, following primary EUA series, we assessed neutralization of D614G and Omicron variants prior to and 28 days after boost. Subset analysis was done in six combinations (N = 10/group): four homologous primary-booster combinations included mRNA-1273 two-dose priming followed by boosting with 100-μg or 50-μg mRNA-1273, Ad26.COV2.S single-dose priming followed by Ad26.COV2.S booster and BNT162b2 two-dose priming followed by BNT162b2 boosting; and two heterologous primary-booster combinations: BNT162b2 followed by Ad26.COV2.S and Ad26.COV2.S followed by BNT162b2. Neutralizing antibody (Nab) titers to D614G on the day of boost (baseline) were detected in 85-100% of participants, with geometric mean titers (GMT) of 71-343 in participants who received an mRNA vaccine series versus GMTs of 35-41 in participants primed with Ad26.OV2.S. Baseline NAb titers to Omicron were detected in 50-90% of participants who received an mRNA vaccine series (GMT range 12.8-24.5) versus 20-25% among participants primed with Ad26.COV2.S. The booster dose increased the neutralizing GMT in most combinations to above 1000 for D614G and above 250 for Omicron by Day 29. Homologous prime-boost Ad26.COV2.S had the lowest NAb on Day 29 (D614G GMT 128 and Omicron GMT 45). Results were similar between age groups. Most homologous and heterologous boost combinations examined will increase humoral immunity to the Omicron variant.

Competing Interest Statement

RLA, CPDI, CMP, DS, RP, MED, AE, HME, RER, MB, ACK, TMB, DD, RNC, JLA, SC, JAZ, SUN, ERB, DJP, and SUN report no competing interests. KEL receives grant awards from Pfizer Inc COVID-19 vaccine research. LAJ receives grant funding from NIH and CDC for vaccine-related assessments, including those of COVID-19 vaccines. ARB has grant funding from Pfizer, Janssen, Merck and Cyanvac for non-Covid-related work and serves as a consultant for GSK and Janssen. CAR has received funds to conduct clinical research from the National Institutes of Health, CDC, BioFire Inc, Genentech, GSK, Janssen, MedImmune, Merck, Micron, Moderna, Novavax, PaxVax, Pfizer, Regeneron, Sanofi-Pasteur. She is co-inventor of patented RSV vaccine technology, which has been licensed to Meissa Vaccines, Inc. JMM has served as a consultant for Merck, Sharp and Dohme for non-Covid-related work. CJ receives funding from the Bill and Melinda Gates Foundation, NIH and CDC, consults for Gilead and Abbvie, serves on a DSMB for MedPace, and receives royalties from UpToDate. MJM has laboratory research and clinical trials contracts for vaccines or MAB vs SARS-CoV-2 with Lilly, Pfizer (exclusive of the current work), and Sanofi; personal fees for Scientific Advisory Board service from Merck, Meissa Vaccines, Inc. and Pfizer RCB receives funding for vaccine trials from Path Nipah and Pfizer. RWF receives funding to perform clinical trials from Pfizer, Moderna, Astra Zeneca and Emergent Health, and he serves on advisory boards for Johnson & Johnson, Merck, Sanofi Pasteur and Seqirus. SE receives funding to her institution from Sanofi Pasteur for a non-Dovid vaccine study. KMN holds a grant from Pfizer, without salary support, for a COVID-19 vaccine study, and salary support from the National Institutes of Health (NIH) for work on multiple COVID-19 vaccine trials DSS is supported by grant awards from NIH/NIAID PCR and JHB report a pending U.S. Patent Application No. 63/025,918 entitled, Coronavirus RNA vaccines and methods of use. DCM receives funding from NIH and Moderna for laboratory studies of COVID-19 vaccine antibody responses.

Clinical Trial

NCT04889209

Funding Statement

The trial was sponsored and primarily funded by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), under award numbers UM1AI48372, UM1AI148373, UM1AI148450, UM1AI148452, UM1AI148573, UM1AI148574, UM1AI148575, UM1AI148576, UM1AI148684, UM1 AI148689 and with support from the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs) contract 75N93019C00050 and NIH Vaccine Research Center. We would like to acknowledge Moderna, Inc., Johnson & Johnson/Janssen, and Pfizer/BioNTech Pharmaceuticals for their collaboration, scientific input, and sharing of documents needed to implement this trial. All products were acquired through the government procurement process.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Advarra has provided ethical and regulatory oversight as part of a multi-center IRB. Local IRBs maintained oversight for each of the ten study sites but had a reliance agreement with Advarra.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵** The Mix and Match Team members are listed in the Supplemental Appendices ClinicalTrials.gov # NCT04889209

  • (Funded by National Institute of Allergy and Infectious Diseases; Clinical Trials.gov number, NCT04889209)

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 14, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting
Kirsten E. Lyke, Robert L. Atmar, Clara Dominguez Islas, Christine M. Posavad, Daniel Szydlo, Rahul PaulChourdhury, Meagan E. Deming, Amanda Eaton, Lisa A. Jackson, Angela R. Branche, Hana M. El Sahly, Christina A. Rostad, Judith M. Martin, Christine Johnston, Richard E. Rupp, Mark J. Mulligan, Rebecca C. Brady, Robert W. Frenck Jr., Martín Bäcker, Angelica C. Kottkamp, Tara M. Babu, Kumaravel Rajakumar, Srilatha Edupuganti, David Dobrzynski, Rhea N. Coler, Janet I. Archer, Sonja Crandon, Jillian A. Zemanek, Elizabeth R. Brown, Kathleen M. Neuzil, David S. Stephens, Diane J. Post, Seema U. Nayak, Paul C. Roberts, John H. Beigel, David Montefiori, the DMID 21-0012 Study Group
medRxiv 2022.01.13.22268861; doi: https://doi.org/10.1101/2022.01.13.22268861
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting
Kirsten E. Lyke, Robert L. Atmar, Clara Dominguez Islas, Christine M. Posavad, Daniel Szydlo, Rahul PaulChourdhury, Meagan E. Deming, Amanda Eaton, Lisa A. Jackson, Angela R. Branche, Hana M. El Sahly, Christina A. Rostad, Judith M. Martin, Christine Johnston, Richard E. Rupp, Mark J. Mulligan, Rebecca C. Brady, Robert W. Frenck Jr., Martín Bäcker, Angelica C. Kottkamp, Tara M. Babu, Kumaravel Rajakumar, Srilatha Edupuganti, David Dobrzynski, Rhea N. Coler, Janet I. Archer, Sonja Crandon, Jillian A. Zemanek, Elizabeth R. Brown, Kathleen M. Neuzil, David S. Stephens, Diane J. Post, Seema U. Nayak, Paul C. Roberts, John H. Beigel, David Montefiori, the DMID 21-0012 Study Group
medRxiv 2022.01.13.22268861; doi: https://doi.org/10.1101/2022.01.13.22268861

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (162)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (862)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8571)
  • Forensic Medicine (4)
  • Gastroenterology (388)
  • Genetic and Genomic Medicine (1758)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1249)
  • Health Policy (622)
  • Health Systems and Quality Improvement (468)
  • Hematology (196)
  • HIV/AIDS (378)
  • Infectious Diseases (except HIV/AIDS) (10318)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (213)
  • Neurology (1681)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (328)
  • Occupational and Environmental Health (451)
  • Oncology (930)
  • Ophthalmology (264)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (538)
  • Pharmacology and Therapeutics (254)
  • Primary Care Research (209)
  • Psychiatry and Clinical Psychology (1775)
  • Public and Global Health (3853)
  • Radiology and Imaging (626)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (521)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)